{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:03:42Z","timestamp":1788869022602,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study examined the impact of venlafaxine and bupropion on the detection of nigrostriatal degeneration by dopamine transporter (DAT)-SPECT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      43 patients (70.7\u2009\u00b1\u20098.6y, 44% female) with [\n                      <jats:sup>123<\/jats:sup>\n                      I]FP-CIT-SPECT under venlafaxine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926, 37.5-225\u00a0mg\/d), bupropion (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916, 150 or 300\u00a0mg\/d) or both (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091) were included retrospectively. The striatal specific [\n                      <jats:sup>123<\/jats:sup>\n                      I]FP-CIT binding ratio (SBR), its left\u2013right asymmetry and the putamen-to-caudate ratio were transformed to z-scores and submitted to a cluster analysis for data-driven categorization.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two clusters were identified. The first cluster (37% cases) showed a Parkinson\u2019s disease (PD)-like pattern: median striatal SBR\/asymmetry\/putamen-to-caudate z-score -4.5\/4.9\/-3.8. The second cluster (63%) showed symmetric reduction with normal intra-striatal gradient: median striatal SBR\/asymmetry\/putamen-to-caudate z-score -2.7\/0.4\/0.2. Patients with follow-up clinical reference diagnoses of neurodegenerative (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098) and non-neurodegenerative (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) parkinsonism fell exclusively into the former or the latter cluster, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Venlafaxine and bupropion cause uniform reduction of the striatal [\n                      <jats:sup>123<\/jats:sup>\n                      I]FP-CIT SBR that can be distinguished from PD-like reductions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-024-06989-z","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T23:31:26Z","timestamp":1732923086000},"page":"1549-1555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion"],"prefix":"10.1007","volume":"52","author":[{"given":"Ivayla","family":"Apostolova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Klutmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-0724","authenticated-orcid":false,"given":"Ralph","family":"Buchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"key":"6989_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/ndt.s1453","volume":"4","author":"PG Frisina","year":"2008","unstructured":"Frisina PG, Borod JC, Foldi NS, Tenenbaum HR. Depression in Parkinson\u2019s disease: health risks, etiology, and treatment options. Neuropsychiatr Dis Treat. 2008;4:81\u201391. https:\/\/doi.org\/10.2147\/ndt.s1453.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6989_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0165-0327(98)00222-5","volume":"51","author":"WD Horst","year":"1998","unstructured":"Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disorders. 1998;51:237\u201354. https:\/\/doi.org\/10.1016\/S0165-0327(98)00222-5.","journal-title":"J Affect Disorders"},{"key":"6989_CR3","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1007\/s00259-023-06171-x","volume":"50","author":"Y Chahid","year":"2023","unstructured":"Chahid Y, Sheikh ZH, Mitropoulos M, Booij J. A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [(123)I]I-FP-CIT SPECT in routine practice. Eur J Nucl Med Mol Imaging. 2023;50:1974\u201387. https:\/\/doi.org\/10.1007\/s00259-023-06171-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6989_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/JCP.0b013e31802e0017","volume":"27","author":"Y Shang","year":"2007","unstructured":"Shang Y, Gibbs MA, Marek GJ, Stiger T, Burstein AH, Marek K, et al. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol. 2007;27:71\u20135. https:\/\/doi.org\/10.1097\/JCP.0b013e31802e0017.","journal-title":"J Clin Psychopharmacol"},{"key":"6989_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/pnp.742","volume":"26","author":"M-K Kanani","year":"2022","unstructured":"Kanani M-K, Gurunathan N. Misdiagnosis of dementia with Lewy bodies due to venlafaxine. Prog Neurol Psychiatry. 2022;26:8\u201310. https:\/\/doi.org\/10.1002\/pnp.742.","journal-title":"Prog Neurol Psychiatry"},{"key":"6989_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.pscychresns.2012.06.004","volume":"211","author":"MC Hsiao","year":"2013","unstructured":"Hsiao MC, Lin KJ, Liu CY, Schatz DB. The interaction between dopamine transporter function, gender differences, and possible laterality in depression. Psychiatry Res. 2013;211:72\u20137. https:\/\/doi.org\/10.1016\/j.pscychresns.2012.06.004.","journal-title":"Psychiatry Res"},{"key":"6989_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00213-002-1166-3","volume":"163","author":"JH Meyer","year":"2002","unstructured":"Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology. 2002;163:102\u20135. https:\/\/doi.org\/10.1007\/s00213-002-1166-3.","journal-title":"Psychopharmacology"},{"key":"6989_CR8","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","volume":"47","author":"S Morbelli","year":"2020","unstructured":"Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885\u2013912. https:\/\/doi.org\/10.1007\/s00259-020-04817-8.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6989_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/a-0807-8137","volume":"58","author":"K Tatsch","year":"2019","unstructured":"Tatsch K, Buchert R, Bartenstein P, Barthel H, Boecker H, Brust P, et al. Dopamine Transporter SPECT with I-123 labelled FP-CIT (DaTSCANTM). Nuklearmedizin. 2019;58:5\u201316. https:\/\/doi.org\/10.1055\/a-0807-8137.","journal-title":"Nuklearmedizin"},{"key":"6989_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000491524","volume":"87","author":"GA Fava","year":"2018","unstructured":"Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87:195\u2013203. https:\/\/doi.org\/10.1159\/000491524.","journal-title":"Psychother Psychosom"},{"key":"6989_CR11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2967\/jnumed.123.266276","volume":"65","author":"R Buchert","year":"2024","unstructured":"Buchert R, Szabo B, Kovacs A, Buddenkotte T, Mathies F, Karimzadeh A, et al. Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole Collimators. J Nucl Med. 2024;65:446\u201352. https:\/\/doi.org\/10.2967\/jnumed.123.266276.","journal-title":"J Nucl Med"},{"key":"6989_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0925-4927(97)00011-5","volume":"74","author":"EH Aylward","year":"1997","unstructured":"Aylward EH, Li Q, Habbak QR, Warren A, Pulsifer MB, Barta PE, et al. Basal ganglia volume in adults with Down syndrome. Psychiatry Res. 1997;74:73\u201382. https:\/\/doi.org\/10.1016\/s0925-4927(97)00011-5.","journal-title":"Psychiatry Res"},{"key":"6989_CR13","first-page":"301","volume":"55","author":"PT Meyer","year":"2011","unstructured":"Meyer PT, Winz OH, Dafotakis M, Werner CJ, Krohn T, Sch\u00e4fer WM. Improved visual [123I]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images. Q J Nucl Med Mol Im. 2011;55:301\u20139.","journal-title":"Q J Nucl Med Mol Im"},{"issue":"43","key":"6989_CR14","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00259-015-3304-2","volume":"I","author":"NL Albert","year":"2016","unstructured":"Albert NL, Unterrainer M, Diemling M, Xiong GM, Bartenstein P, Koch W, et al. Implementation of the European multicentre database of healthy controls for [I-123]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Eur J Nucl Med Mol. 2016;I(43):1315\u201322. https:\/\/doi.org\/10.1007\/s00259-015-3304-2.","journal-title":"Eur J Nucl Med Mol"},{"key":"6989_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00702-016-1586-6","volume":"123","author":"E Makinen","year":"2016","unstructured":"Makinen E, Joutsa J, Johansson J, Maki M, Seppanen M, Kaasinen V. Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism. J Neural Transm. 2016;123:1309\u201318. https:\/\/doi.org\/10.1007\/s00702-016-1586-6.","journal-title":"J Neural Transm"},{"key":"6989_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00259-012-2276-8","volume":"40","author":"A Varrone","year":"2013","unstructured":"Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40:213\u201327. https:\/\/doi.org\/10.1007\/s00259-012-2276-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6989_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","volume":"340","author":"M Tatsumi","year":"1997","unstructured":"Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249\u201358. https:\/\/doi.org\/10.1016\/S0014-2999(97)01393-9.","journal-title":"Eur J Pharmacol"},{"key":"6989_CR18","doi-asserted-by":"crossref","unstructured":"Mizuno Y, Ashok AH, Bhat BB, Jauhar S, Howes OD. Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies. J Psychopharmacol. 2023;37:1058-69. Artn 0269881123120088110.1177\/02698811231200881","DOI":"10.1177\/02698811231200881"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06989-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06989-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06989-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:54:53Z","timestamp":1739944493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06989-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6989"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06989-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4699654\/v1","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"assertion":[{"value":"7 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Waiver of informed consent for the retrospective analysis of anonymized data was obtained from the ethics review board of the general medical council of the state of Hamburg, Germany. All procedures performed in this study were in accordance with the ethical standards of the ethics review board of the general medical council of the state of Hamburg, Germany, and with the 1964 Helsinki declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}